Oligomerix, Inc., a privately held company pioneering the development of disease-modifying therapeutics for Alzheimers disease (AD) and related neurodegenerative disorders, presented results at the Society for Neuroscience 2018 annual meeting highlighting proof-of-concept results for its lead compound using a preventive paradigm. The lead was tested in the human tau transgenic mouse for tau aggregation, modeling a process thought to drive the progression of AD.
These blinded studies were performed independently by Peter Davies, Ph.D., a renowned leader in tau biology and Director, Litwin-Zucker Center for Alzheimers Disease & Memory Disorders, Feinstein Institute for Medical Research.
We will seek to build on the success of the in vivo studies by further evaluating our lead compound in additional in vivo studies treating mice that have already developed tau pathology. The Company is also carrying out additional safety testing that would enable moving its lead into pre-clinical development. Our tau discovery program is highly differentiated from other approaches within the field that have primarily focused tau immunotherapeutic strategies. A small molecule approach, if successful, could enable cost-effective, patient-centered treatment for the rapidly growing, unserved AD market, stated James Moe, Ph.D., MBA, President and CEO of Oligomerix.
Oligomerix, Inc. is focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and maintains an incubator laboratory at the Albert Einstein College of Medicine.
The Company is seeking a strategic partner to help accelerate these important programs into the clinic. For more information, visit www.oligomerix.com.
Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.